Cargando…

Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation

Green tea is manufactured from the leaves of Camellia sinensis and has been shown to possess, among other properties, anticancer, antiobesity, antiatherosclerotic, antidiabetic, antibacterial, and antiviral effects. The beneficial effects of green tea are related to the activities of (−)-epigallocat...

Descripción completa

Detalles Bibliográficos
Autores principales: Frias, Iúri, Neves, Ana Rute, Pinheiro, Marina, Reis, Salette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096752/
https://www.ncbi.nlm.nih.gov/pubmed/27826184
http://dx.doi.org/10.2147/DDDT.S109589
_version_ 1782465518779760640
author Frias, Iúri
Neves, Ana Rute
Pinheiro, Marina
Reis, Salette
author_facet Frias, Iúri
Neves, Ana Rute
Pinheiro, Marina
Reis, Salette
author_sort Frias, Iúri
collection PubMed
description Green tea is manufactured from the leaves of Camellia sinensis and has been shown to possess, among other properties, anticancer, antiobesity, antiatherosclerotic, antidiabetic, antibacterial, and antiviral effects. The beneficial effects of green tea are related to the activities of (−)-epigallocatechin gallate (EGCG). This catechin is very unstable, undergoing degradation and epimerization, which is responsible for the loss of its health benefits. Encapsulation in nanoparticles (NPs) is an effective method to protect EGCG from adverse environmental conditions. In this work, solid lipid NPs (SLN) and nanostructured lipid carriers (NLC) were successfully developed to be used as biocompatible nanocarriers, enhancing the stability of EGCG. The mean diameter of the NPs was found to be around 300–400 nm, which is suitable for oral administration. Moreover, EGCG was effectively encapsulated with a remarkable efficiency of encapsulation of 80% and 90% for SLN and NLC, respectively. In addition, high storage stability of the formulations is expected as they maintain the initial characteristics for 3 months. Limited release of EGCG from the NPs was observed in simulated gastric and intestinal fluids. MTT and lactate dehydrogenase (LDH) assays demonstrated that NPs possess low toxicity, and so have potential to be used for preventive and therapeutic EGCG supplementation.
format Online
Article
Text
id pubmed-5096752
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-50967522016-11-08 Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation Frias, Iúri Neves, Ana Rute Pinheiro, Marina Reis, Salette Drug Des Devel Ther Original Research Green tea is manufactured from the leaves of Camellia sinensis and has been shown to possess, among other properties, anticancer, antiobesity, antiatherosclerotic, antidiabetic, antibacterial, and antiviral effects. The beneficial effects of green tea are related to the activities of (−)-epigallocatechin gallate (EGCG). This catechin is very unstable, undergoing degradation and epimerization, which is responsible for the loss of its health benefits. Encapsulation in nanoparticles (NPs) is an effective method to protect EGCG from adverse environmental conditions. In this work, solid lipid NPs (SLN) and nanostructured lipid carriers (NLC) were successfully developed to be used as biocompatible nanocarriers, enhancing the stability of EGCG. The mean diameter of the NPs was found to be around 300–400 nm, which is suitable for oral administration. Moreover, EGCG was effectively encapsulated with a remarkable efficiency of encapsulation of 80% and 90% for SLN and NLC, respectively. In addition, high storage stability of the formulations is expected as they maintain the initial characteristics for 3 months. Limited release of EGCG from the NPs was observed in simulated gastric and intestinal fluids. MTT and lactate dehydrogenase (LDH) assays demonstrated that NPs possess low toxicity, and so have potential to be used for preventive and therapeutic EGCG supplementation. Dove Medical Press 2016-10-31 /pmc/articles/PMC5096752/ /pubmed/27826184 http://dx.doi.org/10.2147/DDDT.S109589 Text en © 2016 Frias et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Frias, Iúri
Neves, Ana Rute
Pinheiro, Marina
Reis, Salette
Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation
title Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation
title_full Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation
title_fullStr Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation
title_full_unstemmed Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation
title_short Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation
title_sort design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096752/
https://www.ncbi.nlm.nih.gov/pubmed/27826184
http://dx.doi.org/10.2147/DDDT.S109589
work_keys_str_mv AT friasiuri designdevelopmentandcharacterizationoflipidnanocarriersbasedepigallocatechingallatedeliverysystemforpreventiveandtherapeuticsupplementation
AT nevesanarute designdevelopmentandcharacterizationoflipidnanocarriersbasedepigallocatechingallatedeliverysystemforpreventiveandtherapeuticsupplementation
AT pinheiromarina designdevelopmentandcharacterizationoflipidnanocarriersbasedepigallocatechingallatedeliverysystemforpreventiveandtherapeuticsupplementation
AT reissalette designdevelopmentandcharacterizationoflipidnanocarriersbasedepigallocatechingallatedeliverysystemforpreventiveandtherapeuticsupplementation